FARMINGDALE, N.Y., May 4 /PRNewswire-FirstCall/ -- Misonix, Inc. , a developer of ultrasonic medical device technology for the treatment of cancer and other health conditions, today announced that it has been invited by The Long Island Life Sciences Initiative (LILSI) and the Center for Biotechnology, a New York State designated Center for Advanced Technology, to present at the 2006 Life Sciences Industry Summit on Long Island on May 4, 2006. The event has a central theme entitled, “Building Critical Mass: Long Island at the Tipping Point,” which addresses the emergence and expansion of a vibrant life sciences community in the region, while highlighting a focused plan to grow and sustain the local and statewide industry.
The presentation from Misonix will highlight the Company’s high intensity focused ultrasound (HIFU) operations. Misonix recently announced the most impressive data of successful HIFU prostate cancer treatment that has been reported to date any where in the world. The data was the result of a study on “Visually Directed HIFU” treatment of prostate cancer. Visually Directed HIFU is a new, non-invasive HIFU technique available only with the Sonablate(R) 500, a medical device which is manufactured in Farmingdale, Long Island. In addition to HIFU products, Misonix also conducts local research and development as well as manufactures a portfolio of other ultrasonic medical devices for a variety of purposes, including wound debridement, neurosurgery and aesthetic applications.
Presenting on behalf of Misonix will be Dr. W. Paul Constantine, Senior Vice President, Marketing, Sales and New Product Development. Dr. Constantine Dr. Constantine’s career has focused on the development and management of world-class marketing and sales programs for global medical device companies. He graduated from Samuel Merritt College with a doctorate degree after completing undergraduate studies at Loma Linda University.
About the Life Sciences Summit:
The Summit brings together approximately 250 life sciences industry leaders each year to explore issues of strategic importance to industry growth including emerging companies and technologies, financing issues, regulatory affairs, and business development opportunities. Interactive panel sessions will be complimented by an opening plenary, “The Bioethical Challenges of the 21st Century” featuring speakers from Alden March Bioethics Institute at SUNY Albany, and Luncheon keynote, Richard Worzel, C.F.A, a leading North American futurist and best selling author who will present, “The View from 2030: The Future of Life Sciences.” A closing plenary entitled, “Mobilizing the Regions Assets to Find a Cure for Debilitating Diseases,” will be presented by Father Tom Hartman, Founder, Thomas Hartman Foundation for Parkinson’s Research & Celebrity Partner in The God Squad. The May 4th event will take place at the Hilton Long Island/Huntington, and will conclude with a networking reception. For more information: Call 631-632-1743 or visit www.lilsi.org.
About Misonix:
Misonix develops, manufactures, and markets medical, scientific, and industrial ultrasonic and air pollution systems. Misonix’s ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $4 billion annually, Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts with respect to strategic opportunities for its Laboratory and Scientific Division and the affect this activity may have on the other businesses within the Company. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Misonix Contact: Investor Relations Contact: Richard Zaremba Jordan M. Darrow Chief Financial Officer Darrow Associates, Inc. 631-694-9555 631-367-1866 invest@misonix.comjdarrow@optonline.net
Misonix, Inc.
CONTACT: Richard Zaremba, Chief Financial Officer of Misonix,+1-631-694-9555, invest@misonix.com; or Jordan M. Darrow, DarrowAssociates, Inc., +1-631-367-1866, jdarrow@optonline.net
Web site: http://www.misonix.com/
